Aegon Valuation
Is 0Q0Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0Q0Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0Q0Y (€5.92) is trading below our estimate of fair value (€13.72)
Significantly Below Fair Value: 0Q0Y is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0Q0Y?
Key metric: As 0Q0Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0Q0Y's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | €12.73b |
| Market Cap | €9.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 501.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0Q0Y's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
PRU Prudential | 2x | 21.0% | UK£17.5b |
PHNX Phoenix Group Holdings | 0.2x | -27.6% | UK£5.1b |
LGEN Legal & General Group | 1x | 6.9% | UK£13.0b |
CSN Chesnara | 0.9x | n/a | UK£377.5m |
0Q0Y Aegon | 0.8x | -4.5% | €9.7b |
Price-To-Sales vs Peers: 0Q0Y is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does 0Q0Y's PS Ratio compare vs other companies in the GB Insurance Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
RQIH R&Q Insurance Holdings | 0.001x | n/a | US$360.20k |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 0Q0Y is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Insurance industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 0Q0Y's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 1x |
Price-To-Sales vs Fair Ratio: 0Q0Y is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €5.92 | €6.52 +10.0% | 10.8% | €8.00 | €5.40 | n/a | 15 |
| Nov ’25 | €5.87 | €6.27 +6.8% | 11.5% | €7.65 | €4.80 | n/a | 15 |
| Oct ’25 | €5.68 | €6.28 +10.5% | 11.5% | €7.65 | €4.80 | n/a | 15 |
| Sep ’25 | €5.56 | €6.26 +12.7% | 11.7% | €7.65 | €4.80 | n/a | 15 |
| Aug ’25 | €5.77 | €6.11 +5.9% | 14.1% | €7.50 | €4.30 | n/a | 15 |
| Jul ’25 | €5.85 | €6.10 +4.2% | 14.4% | €7.60 | €4.30 | n/a | 15 |
| Jun ’25 | €5.96 | €6.06 +1.6% | 15.3% | €8.00 | €4.30 | n/a | 14 |
| May ’25 | €5.86 | €5.90 +0.7% | 12.0% | €7.00 | €4.30 | n/a | 15 |
| Apr ’25 | €5.65 | €5.84 +3.3% | 11.6% | €7.00 | €4.30 | n/a | 15 |
| Mar ’25 | €5.27 | €5.88 +11.6% | 11.3% | €7.00 | €4.30 | n/a | 16 |
| Feb ’25 | €5.44 | €5.76 +6.0% | 11.5% | €7.00 | €4.30 | n/a | 16 |
| Jan ’25 | €5.26 | €5.49 +4.4% | 12.0% | €6.75 | €4.00 | n/a | 15 |
| Dec ’24 | €5.07 | €5.48 +8.1% | 12.0% | €6.75 | €4.00 | n/a | 15 |
| Nov ’24 | €4.62 | €5.38 +16.6% | 13.6% | €6.75 | €3.60 | €5.87 | 15 |
| Oct ’24 | €4.59 | €5.45 +18.7% | 13.3% | €6.75 | €3.60 | €5.68 | 14 |
| Sep ’24 | €4.76 | €5.39 +13.2% | 13.4% | €6.75 | €3.60 | €5.56 | 15 |
| Aug ’24 | €4.90 | €5.38 +9.7% | 14.1% | €6.75 | €3.60 | €5.77 | 14 |
| Jul ’24 | €4.64 | €5.39 +16.2% | 13.8% | €6.75 | €3.60 | €5.85 | 15 |
| Jun ’24 | €4.16 | €5.33 +28.1% | 15.0% | €6.75 | €3.60 | €5.96 | 14 |
| May ’24 | €4.11 | €5.33 +29.9% | 15.1% | €6.75 | €3.60 | €5.86 | 14 |
| Apr ’24 | €3.95 | €5.38 +36.0% | 15.5% | €6.75 | €3.60 | €5.65 | 14 |
| Mar ’24 | €4.93 | €5.38 +9.1% | 15.5% | €6.75 | €3.60 | €5.27 | 14 |
| Feb ’24 | €5.03 | €5.29 +5.2% | 14.7% | €6.75 | €3.60 | €5.44 | 14 |
| Jan ’24 | €4.80 | €5.18 +8.0% | 14.8% | €6.75 | €3.50 | €5.26 | 15 |
| Dec ’23 | €4.72 | €5.19 +9.9% | 14.8% | €6.75 | €3.50 | €5.07 | 15 |
| Nov ’23 | €4.73 | €5.17 +9.2% | 14.6% | €6.50 | €3.50 | €4.62 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Beazley
UK£4.9b
Provides risk insurance and reinsurance solutions in the United States, the United Kingdom, rest of Europe, and internationally.
BEZL
UK£7.86
7D
7.2%
1Y
40.0%
Grupo Catalana Occidente
€4.3b
Provides insurance products and services worldwide.
0NRN
€36.45
7D
-1.1%
1Y
13.9%
Swiss Re
CHF 28.1b
Provides wholesale reinsurance, insurance, other insurance-based forms of risk transfer, and other insurance-related services worldwide.
SRENZ
CHF 96.62
7D
2.0%
1Y
4.1%